News
NeuroQuant®, CorTechs Labs' FDA-Cleared System for Quantifying Regional Brain Atrophy from MRIs, Used to Identify Patients at Highest Risk for Developing Dementia
A ground-breaking paper published online October 12, 2011 reported that quantitative atrophy measurement significantly improved prediction of future dementia onset in elderly individuals with memory complaints.
New Images of Memory and the Aging Brain - Dr. James Brewer of UCSD discusses NeuroQuant® and volumetric MRI
With exciting advances in brain imaging, new insights into the aging brain have emerged. Join James Brewer, MD, PhD, as he talks about his pioneering work with brain imaging which can lead to earlier and more accurate diagnosis of neurodegenerative illnesses. Clues to maintaining healthy brain function are also discussed.
Invivo to be the key distributor for NeuroQuant® in the US
Invivo, a worldwide leader in the development and manufacturer of MRI clinical solutions, announced at 2010 RSNA show an agreement with CorTechs Labs to be the key distributor for the NeuroQuant® product in the U.S. marketplace.
CorTechs Labs wins the Life Changing Innovation Award for NeuroQuant® volumetric analysis software
On Nov. 18 at BIOCOM's 2010 Med Device & Diagnostics Expo CorTechs Labs has been awarded Life Changing Innovation Award for NeuroQuant® volumetric analysis software. The award is given to a product that has the biggest potential impact on individuals and addresses the greatest medical need.
CorTechs and NeuroQuant® was recently featured in San Diego Business Journal
NeuroQuant® - Translation to Clinical Practice
An article published in Behavioural Neurology (2009) entitled “Fully-automated volumetric MRI with normative ranges: Translation to clinical practice” explains how NeuroQuant®’s fully-automated volumetric MRI capabilities with normative ranges can facilitate wider implementation of volumetric MRI beyond the academic setting.
Measuring Brain Atrophy In Patients With Mild Cognitive Impairment
Scientists at the University of California, San Diego School of Medicine have shown that NeuroQuant® fully automated Volumetric MRI is effective in predicting the progression from mild cognitive impairment (MCI) to Alzheimer's disease. The procedure can be readily used in clinics to measure brain atrophy, and may help physicians to predict decline in MCI patients. Read press release or PubMed citation
NeuroQuant® Results Published in American Journal of Neuroradiology.
Brewer JB, Magda S, Airriess C, Smith ME (2008). Fully-Automated Quantification of Regional Brain Volumes for Improved Detection of Focal Atrophy in Azheimer’s Disease. AJNR Am J Neuroradiology.
NeuroQuant® highlighted on Apple, Inc Science website!
In a feature entitled "Breakthrough: Unmasking Early-Stage Alzheimer's Disease - Reducing MRI Analysis Time from 100 Hours to Less than 10 Minutes" Apple discusses NeuroQuant® and profiles UCSD neuroradiologist Dr James Brewer, who uses NeuroQuant® extensively in his research and clinical practice.
NeuroQuant® Results Presented at the 2008 International Conference on Alzheimer's Disease, Chicago, July 26-31 2008.
Automated volumetric analyses performed with NeuroQuant® were shown to
be highly reliable across repeated imaging sessions and equivalent in
accuracy to volumetric analysis performed by an expert human
neuroanatomist. Results produced by NeuroQuant® were also shown to be
highly sensitive to the medial temporal temporal lobe atrophy
characteristic of early stage Alzheimer's disease.
NeuroQuant® selected as Finalist in 2007 Most Innovative New Product Awards (10/1/07)
CorTechs Labs NeuroQuant® was selected from over ninety nominations in seven categories to be honored through the MIP Awards, celebrating excellence among San Diego innovators and entrepreneurs for the past 20 years. Click here to read the press release.
Press Release (9/20/07)
CorTechs Labs, Inc. Introduces NeuroQuant®: the First Medical Device for Quantifying Regional Brain Atrophy in Patients with Neurodegenerative Disorders
